ArticleNature communications2026
Allylrhodanine-processed all-small-molecule organic solar cell achieves an 18.43% efficiency breakthrough.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polar-Twisted Electron-Transport Layer Simultaneously Breaks Efficiency-Flexibility-Cost Limits in Organic Solar Cells.Nano-micro letters · 2026Article
- Optimized Molecular Nucleation Behaviors in Highly Efficient Organic Solar Cells Enabled by a Bezothiophene-Based Solid Additive.Polymers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Solid additives (SAs) improve organic solar cells (OSCs) morphology and performance, yet, their efficiency in all-small-molecule (ASM) OSCs is limited by strong donor-acceptor crystallinity, and the underlying mechanisms remain unclear. Herein, structurally resembling the MPhS-C2 donor, 3-allylrhodanine (3-AR) as a SA enables precise control over the active layer morphology. Interesting, combined theoretical calculations and thin-film morphology analyses reveal 3-AR preferentially interacts with acceptor N3, thereby directing morphology evolution. Moreover, 3-AR effectively narrows the film formation window, suppressing lateral over-aggregation and crystallization, while promoting vertical donor-acceptor homogeneity. This optimized morphology synergistically facilitates efficient charge dissociation and collection, suppresses both bimolecular and trap-assisted recombination, and extends the lifetimes of excitons and charge carriers. Therefore, the 3-AR-treated MPhS-C2:N3 device achieves a remarkable power conversion efficiency (PCE) of 18.43% (certified 18.16%)-the highest reported for binary ASM-OSCs. This work shows additive efficacy is governed by balanced selective interactions, not by simplistic structural similarity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.